1. Home
  2. PFAI vs LIXT Comparison

PFAI vs LIXT Comparison

Compare PFAI & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PFAI

Pinnacle Food Group Limited

N/A

Current Price

$2.32

Market Cap

27.1M

ML Signal

N/A

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$3.33

Market Cap

25.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PFAI
LIXT
Founded
2015
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.1M
25.4M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
PFAI
LIXT
Price
$2.32
$3.33
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.2K
84.6K
Earning Date
02-10-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,497,672.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
28.80
N/A
52 Week Low
$1.30
$0.64
52 Week High
$4.93
$6.26

Technical Indicators

Market Signals
Indicator
PFAI
LIXT
Relative Strength Index (RSI) 54.42 42.48
Support Level $2.05 $3.04
Resistance Level $2.38 $3.53
Average True Range (ATR) 0.23 0.33
MACD 0.02 0.01
Stochastic Oscillator 36.13 43.92

Price Performance

Historical Comparison
PFAI
LIXT

About PFAI Pinnacle Food Group Limited

Pinnacle Food Group Ltd is a provider of smart farming solutions focused on vertical and hydroponic farming. The company focuses on promoting sustainable food security by developing and building customized smart farming systems for customers based on the systematic integration of technology, hardware, and software, coupled with a full range of integrated supply and technical services. It sells hydroponic growing systems and technical support services to individual households and community groups, and is developing a hydroponic growing system for urban farms. Geographically, the company generates the majority revenue from Canada, followed by New Zealand.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: